A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

NCT05936151 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

Overweight or Obesity
CKD
Type 2 Diabetes

Interventions

DRUG: Retatrutide
DRUG: Placebo

Sponsor

Eli Lilly and Company